share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144:擬議出售證券
美股sec公告 ·  05/15 04:33
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 20,054 Class A shares of the company, with an aggregate market value of $202,934.74, on 05/14/2024. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 94,503 shares were sold for gross proceeds of $984,984.41.
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 20,054 Class A shares of the company, with an aggregate market value of $202,934.74, on 05/14/2024. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 94,503 shares were sold for gross proceeds of $984,984.41.
Recursion Pharmicals, Inc.董事布萊克·博格森定於2024年5月14日出售該公司的20,054股A類股票,總市值爲202,934.74美元。這些股票最初於2016年1月9日作爲創始人股票收購,這是發行人補償的一種形式。此次計劃出售是在過去三個月進行的一系列交易之後進行的,共出售了94,503股股票,總收益爲984,984.41美元。
Recursion Pharmicals, Inc.董事布萊克·博格森定於2024年5月14日出售該公司的20,054股A類股票,總市值爲202,934.74美元。這些股票最初於2016年1月9日作爲創始人股票收購,這是發行人補償的一種形式。此次計劃出售是在過去三個月進行的一系列交易之後進行的,共出售了94,503股股票,總收益爲984,984.41美元。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。